Advertisement

NLS Idogen

Agreement - April 6, 2022

Idogen signs agreement with two Nordic CROs

Idogen has signed a strategic collaboration agreement with two contract research organizations, Danish Klifo and Finnish 4Pharma, which will together with Idogen run the clinical phase 1/2a study with IDO 8. IDO 8 is a new cell therapy for patients with severe hemophilia who have developed antibodies to their treatment with coagulation factor VIII. The […]

Pharma Business - March 3, 2020

Idogen publishes prospectus in connection with the forthcoming rights issue

The Board of Directors of Idogen has, due to the company’s forthcoming rights issue that was announced on January 28, 2020, prepared an EU Growth Prospectus which now has been approved and registered by the Swedish Financial Supervisory Authority. “The forthcoming Rights Issue has the potential to strengthen Idogen’s capabilitiy to become a successful and […]

Drug Development Pharma - January 20, 2020

Idogen’s cell technology advanced to large-scale production

Idogen has announced that the company’s technology platform for tolerogenic dendritic cell generation has been successfully advanced from pilot to production-scale. Results from completed tests show that the technology platform can now generate functional cells in considerably larger volumes than previously possible, states the company. As the next step, Idogen now initiates the partnership with […]

In a new job - August 13, 2019

Idogen appoints a new CEO

Anders Karlsson has been appointed new CEO for the company and he will take up his new position on August 19, 2019. Anders Karlsson has a broad experience from a range of pharma and medtech companies, including leading positions at Novartis and Olerup International. ”Idogen has ground-breaking development projects within immunology and transplantation, areas which […]

Intellectual Property - December 14, 2017

Idogen has been granted a patent in the USA

The United States Patent & Trademark Office has granted a patent covering the company’s technology for tolerogenic immune therapy. This technology forms the basis of the new therapies developed by Idogen to prevent the immune system from disabling the standard treatment of hemophilia, as well as causing rejection of transplanted organs. Patents in the same […]

In a new job - March 31, 2017

Idogen recruits new CMO

Idogen has recruited Dr. Steven Glazer to the position of Chief Medical Officer (CMO) commencing the 1st of April. The company hopes that this appointment means a strengthening of the organization for future clinical studies, initially in hemophilia A. “I look forward to working with Idogen and hemophilia again – a patient group I’ve worked […]

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.